$28.24
0.08[0.28%]
At close: May 7
$28.24
0[0.00%]
PreMarket: 4:23AM EDT
Latest News for Pfizer Stock (NYSE:PFE)
Pfizer Stock (NYSE: PFE)
Categories: All
Monday, May 06, 2024
Friday, May 03, 2024
Thursday, May 02, 2024
- Pfizer Prospects Garner Mixed Sentiment From Analysts: 'Finally, The Pivot Investors Have Been Waiting For'Vandana Singh - 4 days ago
- 10 Health Care Stocks Whale Activity In Today's SessionBenzinga Insights - 4 days ago
- Morgan Stanley Maintains Equal-Weight on Pfizer, Raises Price Target to $29Benzinga Newsdesk - 4 days ago
- Pfizer shares are trading higher on continued strength after the company, on Wednesday, reported better-than-expected Q1 financial results. Josh Brown, on CNBC, made a bullish call on the stock.Benzinga Newsdesk - 4 days ago
- Live On CNBC, Josh Brown Announces He Has "Doubled Down On Pfizer"Benzinga Newsdesk - 4 days ago
- BMO Capital Reiterates Outperform on Pfizer, Raises Price Target to $36Benzinga Newsdesk - 4 days ago
- Pfizer Unusual Options ActivityBenzinga Insights - 4 days ago
- Investor Optimism Improves Slightly Following Fed DecisionAvi Kapoor - 5 days ago
Wednesday, May 01, 2024
- Carvana, Enovix, Pfizer, Nio, Tesla: Why These 5 Stocks Are On Investors' Radars TodayBenzinga Neuro - 5 days ago
- Dow Jumps 200 Points Following Fed Decision; Pfizer Earnings Top EstimatesAvi Kapoor - 5 days ago
- US Stocks Mixed Ahead Of Fed Meeting, Chipmakers Tumble After AMD Earnings, Bitcoin Sinks: What's Driving Markets Wednesday?Piero Cingari - 5 days ago
- Pfizer Exec Says Co Is Progressing On Retail Contracting For RSV Vaccine; RSV Vaccine Performance Was In Line With Expectations In QTR; Patent Term Extension, If Granted, Could Extend U.S. Exclusivity For Heart Disease Drug Vyndamax To Dec 2028Benzinga Newsdesk - 5 days ago
- Pfizer Embraces Direct-To-Consumer Model For Covid Antiviral, Says Comirnaty Revenues Continue To Perform Consistently With ExpectationsVandana Singh - 5 days ago
- GSK Sees Strong Demand For Vaccines and Asthma Drugs, Raises Annual OutlookVandana Singh - 5 days ago
- Pfizer Sees FY24 Revenues $58.5B-$61.5B Vs $62.92B EstimateBenzinga Newsdesk - 5 days ago
- Pfizer Sees FY24 Adj. EPS $2.15-$2.35 Vs $2.76 EstimateBenzinga Newsdesk - 5 days ago
- Pfizer shares are trading higher after the company reported better-than-expected Q1 financial results.Benzinga Newsdesk - 5 days ago
- Pfizer Q1 2024 Adj EPS $0.82 Beats $0.54 Estimate, Sales $14.90B Beat $14.20B EstimateBenzinga Newsdesk - 5 days ago
- FT Earlier Reported Pfizer To Sell Covid And Migraine Drugs Directly To ConsumersBenzinga Newsdesk - 5 days ago
- Wall Street Set To Open Lower After AMD Earnings Disappoint As Traders Look To Fed's Powell For Relief: Why This Analyst Sees Incoming Summer RallyShanthi Rexaline - 5 days ago
- Investor Sentiment Falls, Dow Snaps Five-Month Win StreakAvi Kapoor - 6 days ago
- Amazon, Pfizer And 3 Stocks To Watch Heading Into WednesdayAvi Kapoor - 6 days ago
Tuesday, April 30, 2024
Monday, April 29, 2024
- FDA OKs Seagen's Tivdak (tisotumab vedotin-tftv) For Cervical CancerBenzinga Newsdesk - Apr 29, 2024, 3:53PM
- What Makes Amazon Attractive Ahead of Q1 Earnings?Zacks - Apr 29, 2024, 12:11PM
- mRNA Is Promising A Breakthrough In Fighting CancerUpwallstreet - Apr 29, 2024, 10:02AM
- FDA Approves Labcorp's nAbCyte Anti-AAVRh74var HB-FE, Companion Diagnostic To Determine Patient Eligibility For Treatment With Beqvez (Fidanacogene Elaparvovec-dzkt), Pfizer's Recently FDA-Approved Hemophilia B Gene TherapyBenzinga Newsdesk - Apr 29, 2024, 7:04AM
- Pfizer to Present Cancer Therapies at ASCO Annual Meeting, Including Advances in ADCs and Bispecific AntibodiesBenzinga Newsdesk - Apr 29, 2024, 6:47AM
- Will Earnings Cheer Continue To Buoy Markets? Apple, Amazon, Pfizer, Coinbase Lead Flurry Of Q1 Reports This WeekShanthi Rexaline - Apr 29, 2024, 1:51AM
Friday, April 26, 2024
- COVID-19 Patent Dispute Sorted: Acuitas Therapeutics and CureVac Reach Settlement In Patent BattleVandana Singh - Apr 26, 2024, 2:45PM
- FDA Green Lights Pfizer's Gene Therapy For Rare Bleeding Disorder HemophiliaVandana Singh - Apr 26, 2024, 2:30PM
- Pfizer's Options: A Look at What the Big Money is ThinkingBenzinga Insights - Apr 26, 2024, 10:02AM
- Pfizer Says U.S. FDA Approved Company's BEQVEZ (fidanacogene elaparvovec-dzkt), A One-Time Gene Therapy For Adults With Hemophilia B; Company Now Plans Launching An Innovative Warranty Program Based On Durability Of Patient Response To TreatmentBenzinga Newsdesk - Apr 26, 2024, 6:48AM
Thursday, April 25, 2024
- Bristol-Myers Q1 Loss Narrower Than Expected, Sales BeatZacks - Apr 25, 2024, 10:16PM
- Pfizer and BioNTech shares are trading lower amid reports GSK is suing the companies alleging patent infringement concerning mRNA technology used in their COVID-19 vaccines.Benzinga Newsdesk - Apr 25, 2024, 3:34PM
- What's Going On With Pfizer Stock On Thursday?Vandana Singh - Apr 25, 2024, 1:51PM
- Wall Street's Most Accurate Analysts' Views On 3 Health Care Stocks Delivering High-Dividend YieldsAvi Kapoor - Apr 25, 2024, 7:54AM